Tuesday, March 21, 2023
Clinical Advances in
In the primary care setting, the optimal management of severe asthma remains a serious clinical challenge. Many patients do not receive early or appropriate evaluation, and selection of the best treatment is suboptimal. Oral corticosteroids are often overused, and many primary care providers (PCPs) are uncertain about the role of biologics in the treatment algorithm. Referral to respiratory specialists is also delayed, thus compromising the best case for these patients.
Developed in partnership with the International Primary Care Respiratory Group (IPCRG) and the World Allergy Organisation (WAO), this educational curriculum will update physicians on the most current treatment guidelines and best practice regarding the management of severe asthma.
View programs for: Primary Care Physicians Pulmonary Specialists
Supported by independent funding from
Presented through a collaboration between Medscape and
A downloadable educational resource comprising key slides from this educational curriculum.
Download
International Primary Care Respiratory Group Chair
IPCRG President
Assistant Professor
University of Crete
Crete, Greece
International Primary Care Respiratory Group Member
Assistant Professor of Family Medicine
Institute for Biomedical Sciences Abel Salazar
University of Porto
Porto, Portugal
International Primary Care Respiratory Group Member
General Practitioner
Clinical Academic Fellow
University of Edinburgh
Edinburgh, United Kingdom
World Allergy Organisation Chair
Past-President
World Allergy Organization
Hospital Quirón Bizkaia
Errandio, Spain
World Allergy Organisation Member
President-Elect
World Allergy Organization
Sagamihara National Hospital
Sagamihara, Kanagawa, Japan
World Allergy Organisation Member
Immediate Past-President
World Allergy Organization
Clinical El Avila
Caracas, Venezuela
Patient Advocate
CEO
Allergy & Asthma Network
Vienna, Virginia, United States
International Primary Care Respiratory Group Chair
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation
Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation
Received grants for clinical research from: GlaxoSmithKline Greece
International Primary Care Respiratory Group Member
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca; GlaxoSmithKline
Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation
International Primary Care Respiratory Group Member
Has disclosed the following relevant financial relationships
Received grants for clinical research from: Asthma UK; Innovate UK
World Allergy Organisation Chair
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Merck, Sharpe, and Dohme, Corp.; Sanofi
Served as a speaker or a member of a speakers bureau for: Hikma; Roxall; Sanofi
World Allergy Organisation Member
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Kyorin; Kyowa Medics; Mahuro; Mitsubishi Tanabe Pharma Corporation; Mylan EPD; Thermo Fisher Scientific Inc.
World Allergy Organisation Member
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Alakos; Novartis Pharmaceuticals Corporation
Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation
Patient Advocate
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca; GlaxoSmithKline